Previous Close | 5 |
1-Year Change | 47.93% |
6-Months Change | -8.76% |
3-Months Change | -6.54% |
Moving Avg (50d) | 4.8046 |
Moving Avg (200d) | 4.9463 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 287.6M |
Beta (3-Years) | 0.71 |
Revenue Growth (ttm) | -17.86% |
Net Profit Margin (ttm) | 5.56% |
Return On Assets (ttm) | 1.83% |
EPS (ttm) | 0.21 |
PE Ratio (ttm) | 23.81 |
Dividend Yield | % |
Asset Description: | Vanda Pharmaceuticals Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-18 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
4.998 | 5.145 | 5.243 | 5.39 | 5.635 | 5.88 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |